Ainos Inc Stock Price, News & Analysis

Ainos, Inc. (NASDAQ:AIMD) has prepaid its remaining convertible note financing with Lind Global Fund II LP, totaling approximately $1.67 million. The company, focused on AI-powered point-of-care testing and low-dose interferon therapeutics, maintains a robust financial runway of over 12 months after the prepayment. Ainos has recently enrolled its first subject for VELDONA®-based animal drug in treating FCGS and is developing the next-gen Ainos Flora powered by AI Nose, implementing NVIDIA CUDA. The company's CEO, Chun-Hsien Tsai, expressed gratitude for The Lind Partners' financial support and reaffirmed Ainos' commitment to building shareholder value.

Ainos (NASDAQ:AIMD) reported its Q2 2024 financial results, highlighting progress in its VELDONA® animal health initiatives. The company enrolled its first subject for an FCGS clinical study, marking a shift towards drug development in animal health. Ainos raised $9 million through convertible note financing, ensuring a 12+ month financial runway. Q2 2024 saw nominal revenues and a net loss of $3,195,022. R&D expenses increased to $1,978,756, while SG&A expenses rose to $1,044,880. The company's cash position improved to $8,014,098 as of June 30, 2024. Ainos is advancing its AI Nose technology and VELDONA® human drug candidates, aiming to maximize long-term shareholder value.

Ainos (NASDAQ:AIMD) has enrolled the first subject for its Taiwanese clinical study of VELDONA®-based animal drug in treating feline chronic gingivostomatitis (FCGS). The study aims to evaluate the safety, tolerability, and efficacy of low-dose oral interferons for FCGS treatment. With 30 subjects expected to be enrolled by end-2024, the trial report is anticipated to be finalized in Q1 2025. This milestone marks a significant step in Ainos' efforts to expand VELDONA's market and develop innovative treatments for cats with FCGS. The potential market is substantial, with an estimated 5.8 to 8.3 million cats in the U.S. affected by FCGS. The global pet dental health market is projected to reach US$9.98 billion by 2030, growing at a CAGR of 6.25% from 2023.

Ainos announces significant progress in the clinical trials of its AI Nose-powered Ainos Flora device, designed for rapid, non-invasive detection of bacterial, fungal, and common sexually transmitted infections in women. The trials, conducted at four major medical centers in Taiwan, successfully tested 75 cases, validating the AI algorithm's accuracy through real-world data incorporation and comprehensive data standardization.

Building on current trial success, Ainos aims to develop a next-gen Ainos Flora with NVIDIA CUDA, targeting Q3 for design completion and Q4 for clinical trials. The new device will feature improvements for at-home testing, addressing growing demand for decentralized healthcare solutions. The STI testing market is projected to reach $256 billion by 2028, with POCT accounting for 31%.

Ainos' ongoing innovation in AI and medical technology is supported by over 50 patents. The Ainos Flora device won the 2021 iF's Medicine/Health Design Award, highlighting its effectiveness and user-friendly design for home healthcare.

Ainos announced a clinical study for a new VELDONA-based drug aimed at treating feline chronic gingivostomatitis (FCGS). The study will evaluate the efficacy of low-dose oral interferons and is expected to run from May 24, 2024, to March 31, 2025. This initiative follows a Memorandum of Understanding with SIDSCO Biomedical and aims to expand Ainos' presence in the pet care market. VELDONA, initially approved in 1985 for feline leukemia and canine parvovirus, has shown systemic effects in various species, making it a promising candidate for FCGS treatment. The trial will include 30 cats and assess health improvements and potential steroid dosage reductions.

Ainos, a diversified healthcare company, released its Q1 2024 financial results. The company reported a strategic shift from COVID-19 rapid test kits, affecting near-term revenues, with Q1 revenue dropping to $20,729 from $49,164 in Q1 2023. Cost of revenues also decreased to $26,754 from $100,848. Despite this, gross profit improved, narrowing the loss to $6,025 from a $51,684 loss a year ago. Total operating expenses rose to $3.11M, attributed to higher clinical trial fees and research costs. Net loss widened to $3.31M from $2.52M. Recent financing efforts secured $9M in growth capital and an additional $1.75M in January 2024, bolstering Ainos' position for continued growth. CEO Chun-Hsien Tsai emphasized the focus on AI Nose and VELDONA technologies, exploring new markets, and advancing clinical studies.

Ainos, Inc. raises $9 million in growth capital through a convertible note with an existing shareholder. The capital will be used to scale up the company's VELDONA and AI Nose growth initiatives. Ainos aims to advance its AI Nose platform and VELDONA investigational new drugs, propelling the company forward in advancing clinical studies and pursuing out-licensing opportunities.